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Abstract 21 
 22 
The blood-brain barrier (BBB) regulates molecular trafficking, protects against pathogens, and 23 
prevents efficient drug delivery to the brain. Models to date failed to reproduce the human anatomical 24 
complexity of brain barriers, contributing to misleading results in clinical trials. To overcome these 25 
limitations, a novel 3-dimensional BBB microvascular network model was developed via 26 
vasculogenesis to accurately replicate the in vivo neurovascular organization. This microfluidic 27 
system includes human induced pluripotent stem cell-derived endothelial cells, brain pericytes, and 28 
astrocytes as self-assembled vascular networks in fibrin gel. Gene expression of membrane 29 
transporters, tight junction and extracellular matrix proteins, was consistent with computational 30 
analysis of geometrical structures and quantitative immunocytochemistry, indicating BBB maturation 31 
and microenvironment remodeling. Confocal microscopy validated microvessel-pericyte/astrocyte 32 
dynamic contact-interactions. The BBB model exhibited perfusable and selective microvasculature, 33 
with permeability lower than conventional in vitro models, and similar to in vivo measurements in rat 34 
brain. This robust and physiologically relevant BBB microvascular model offers an innovative and 35 
valuable platform for drug discovery to predict neuro-therapeutic transport efficacy in pre-clinical 36 
applications as well as recapitulate patient-specific and pathological neurovascular functions in 37 
neurodegenerative disease. 38 
  39 
Introduction  40 
 41 
The blood-brain barrier (BBB) and blood-spinal cord barrier help maintain brain homeostasis [1] by 42 
regulating the transport of necessary nutrients, ions, and hormones, while preventing the entry of 43 
neurotoxins or pathogens into the brain owing to a complex membrane transport mechanism [2]. The 44 
BBB consists of specialized endothelial cells (ECs) interconnected by junctional complexes including 45 
tight junctions (TJs) and adherens junctions, surrounded by pericytes (PCs) and astrocytes (ACs), and 46 
ensheathed in a basal lamina. Each of these specialized features contributes to BBB integrity, and to 47 
the control of transport processes [3]. Loss of BBB integrity is associated with Alzheimer's disease  48 
[4][5], Parkinson’s disease [6], and multiple sclerosis [7], as well as with brain cancer [8]. 49 
Furthermore, the BBB regulates active and passive transport of solutes into the brain [9][10], posing 50 
an obstacle to drug delivery for the treatment of neurological diseases and brain tumors [11][12].  51 
 52 
For these reasons, preclinical models of the BBB are developed to understand its role in the 53 
pathogenesis of neurological diseases as well as to evaluate drug permeability. For years, in vivo 54 
animal models have been used to model the BBB and study drug delivery [13]. Although these 55 
techniques are considered the gold standard, 80% of successful drug candidates in animal models 56 
later failed in clinical trials [14][15].  57 
 58 
To optimize the design of innovative therapies and drug carriers, a robust, reliable, and cost-effective 59 
in vitro BBB model that adequately reflects human in vivo conditions is required [16][17]. For several 60 
decades, transwell assays have been widely adopted to assess drug permeability by culturing a 61 
confluent monolayer of ECs in the absence or presence of PCs or ACs [18]. Although this system is 62 
reproducible and easy to use, it has limitations in mimicking fundamental BBB features and 63 
microenvironmental complexities such as cell-cell or cell-matrix interactions, compromising its 64 
ability to accurately model brain capillaries in terms of junctional proteins and membrane transporter 65 
expression [17][19][20]. Recently, BBB spheroids have been developed to study organogenesis and 66 
the transport of brain penetrating agents [21][22]. Although these systems are cost-effective, they are 67 
limited in their ability to recreate a realistic and relevant BBB morphology. As an alternative to 68 
simple culture models, microfluidic technology offers a promising tool for reconstituting the BBB 69 
with several advantages: microfluidic systems allow for precise control of the 3D cellular and 70 
extracellular matrix (ECM) microenvironment, while providing a platform for the study of cellular 71 
and structural responses to various stimuli. These systems mimic the complex cellular interactions 72 
and structures found in many tissues or organs in vivo, and are thus referred to as 'organ-on-a-chip' 73 
[23][24]. Recently, efforts to reconstitute a 3D BBB model within a microfluidic system have 74 
accelerated with the development of organ-on-a-chip assays to study immune cell transmigration [25], 75 
metastatic cancer extravasation to the brain [26], as well as vessel formation in a tubular shape [27]. 76 
However, systems to date have relatively large diameters (~ 600-800 µm) [27] compared to the 77 
dimension of human BBB vasculature in vivo (arterioles and venules 10-100 µm; capillaries 7-10 78 
µm) [28][29], and fail to recapitulate BBB microvasculature morphology and development in terms 79 
of mature cell-cell interactions via natural biological processes, as well as physiological blood flow 80 
rates and wall shear stresses needed to activate mechanosensing/mechanotransduction pathways, thus 81 
altering realistic transport exchange mechanisms at the level of brain capillaries [30][31]. 82 
 83 
Two microfluidic models have been recently reported using a co-culture of human ECs and rat 84 
neurons and ACs. One incorporated a compartmentalized 3D monolayer of human cerebral 85 
microvascular ECs in co-culture with primary rat ACs and neurons [32]. In a separate study, similar 86 
to the previous model [33], a BBB microvascular network (μVN) platform created by a 87 
vasculogenesis-like process, culturing human umbilical vein endothelial cells (HUVECs) in a 3D 88 
ECM-mimetic hydrogel showed that direct interaction with neural tissue from the rat cortex was 89 
responsible for the low permeability values measured [34].  90 
 91 
However, while co-cultures with cells from different species are advantageous in terms of 92 
accessibility and ease of genetic manipulations, cross-species compatibility remains a concern 93 
regarding the relevance of these results to human physiology [35]. Moreover, HUVECs offer a poor 94 
model for cerebral vasculature, while PCs, recognized to be a key component of the BBB [35], have 95 
not been considered in these models [32][34]. 96 
 97 
To address the main limitations of the current state-of-the-art models, we reasoned that a BBB model 98 
developed from human cells co-cultured in a 3D microenvironment would better replicate the human 99 
BBB, based on the hypothesis that the co-culture arrangement could support the maturation and 100 
differentiation of human iPS cell-derived endothelial cells (iPSC-ECs) into BBB microvascular cells. 101 
Hence, a 3D BBB microfluidic model was designed consisting of self-assembled μVNs from human 102 
iPSC-ECs as well as human primary brain PCs, and human primary ACs, where all cell types 103 
spontaneously assembled into a modular organization reproducing the BBB structure being in 104 
dynamic and direct contact with each other. 105 
 106 
BBB functionality was evaluated by progressive increase of co-culture complexity up to a tri-culture 107 
of iPSC-ECs, PCs, and ACs. Confocal imaging and immunocytochemistry, permeability 108 
measurements and gene expression analysis were used to quantitatively assess BBB characteristics. 109 
Such human 3D BBB model has unique biological features, representing a promising platform for in 110 
vitro preclinical experimentation. 111 
  112 
Materials and methods 113 
 114 
Fabrication of the microfluidic device (micro-device/macro-device) 115 
The 3D microfluidic systems were composed of polydimethylsiloxane (PDMS; Sylgard 184; Dow 116 
Corning, MI, USA) with a single layer microchannel and two fluid channels, fabricated by soft 117 
lithography [36] (Fig. 1c, Supplementary Fig. 1a-b). Elastomer and curing agent were mixed (10:1 118 
volume ratio), degassed and poured onto a silicon master and cured overnight at 60°C. I/O holes were 119 
created with biopsy punches, then the device was taped to remove dust and sterilized as previously 120 
described [37]. The PDMS micro and macro-devices were treated with oxygen plasma (Harrick 121 
Plasma), then bonded to a glass coverslip (Fisher Scientific) coated with poly(D-lysine 122 
hydrobromide) (PDL, Sigma-Aldrich) solution (1 mg/ml) and, finally, placed in an incubator for 3 h 123 
at 37°C, rinsed 3 times and dried overnight.  124 
 125 
 Cell culture and device seeding of BBB self-assembled vascular network model 126 
Human iPSC-ECs (Cellular Dynamics International, CDI) were subcultured on flasks coated with 127 
human fibronectin (30 µg/ml, Millipore) in vascular medium (VascuLife VEGF Medium Complete 128 
Kit, icell media supplement, CDI). Pericytes and astrocytes isolated from human brain (ScienCell), 129 
were cultured in growth medium (ScienCell) on a poly-l-lysine (Sigma-Aldrich) coated flask, and 130 
maintained in a humidified incubator (37 °C, 5% CO2), replacing the medium every 2 days. Cells 131 
were detached using TrypLE (for iPSC-ECs) and 0.025% trypsin/EDTA for other cell types (Thermo 132 
Fisher). Experiments were performed between passages 3 and 5 for all cells.  133 
 134 
Fibrinogen (6 mg/ml) and thrombin (100 U/ml) from bovine plasma (Sigma-Aldrich) were separately 135 
dissolved in sterile PBS. Then, thrombin was mixed with 1ml of EGM-2 MV (Lonza) and placed on 136 
ice. Cells were detached and spun down at 1200 rpm for 5 min and cell pellet was resuspended in 137 
EGM-2 MV 4 U/ml thrombin. Cell suspension was mixed with fibrinogen (final concentration 3 138 
mg/ml) at 1:1 volume ratio. The mixture was quickly pipetted into the gel filling ports. Devices were 139 
placed in a humidified enclosure and allowed to polymerize at room temperature (RT) for 15 min 140 
before the fresh medium was introduced to fluidic channels. iPSC-ECs medium was supplemented 141 
with 50 ng/ml of vascular endothelial growth factor (VEGF, Peprotech), for the first four days of 142 
culture. Medium for the tri-culture condition was supplemented with 1% (vol/vol) Astrocyte Growth 143 
factor (AGF, astrocyte growth supplement, ScienCell).   144 
 145 
Three different cell combinations were tested: 1) iPSC-ECs mono-culture (6×106 cells/ml), 2) co-146 
culture iPSC-ECs+PCs (add 2×106 cells/ml PCs) and 3) tri-culture of iPSC-ECs+PCs+ACs (add 147 
2×106 cells/ml ACs). After fibrin polymerization, medium channels were coated for 30 min in an 148 
incubator (37°C 5% CO2) with human fibronectin (60 µg/ml) to promote endothelial cell adhesion. 149 
In each case, iPSC-ECs were subsequently seeded at 2x106 cells/ml in EBM-2 (Lonza) into the fluidic 150 
channels to reduce diffusion of fluorescent dyes into the gel. Non-adherent cells were removed after 151 
2 h. The device was kept in an incubator for 7 days (37 °C, 5% CO2), 200 µl of medium was replaced 152 
every 24 h. Devices prepared in this manner were used for both permeability measurements and 153 
immunocytochemical staining. PC conditioned medium was collected after 3 days, from a T75 flask 154 
of PCs culture, mixed 1:1 volume ratio with fresh medium and replaced every 24 h in the iPSC-ECs 155 
mono-culture in the microfluidic device. 156 
 157 
The in vitro BBB model was developed by co-culturing human iPSC-ECs, and human brain PCs and 158 
ACs to mimic certain aspects of the organization and structure of the brain microcirculation observed 159 
in vivo (Fig. 1a,b). The BBB model formed by a vasculogenesis-like process, consisted of a well-160 
connected and perfusable μVN in a microfluidic device (Fig. 1c, Supplementary Fig. 1a), interacting 161 
via paracrine, juxtacrine and mechanical signaling[38][39]. iPSC-ECs seeded in the side media 162 
channels reduced leakage through the side walls of the central gel region and promoted the formation 163 
of patent vessel connections to the media channels, facilitating flow into the network (Fig. 1d,e). 164 
 165 
Figure 1: Blood-brain barrier and in vitro microvascular network model. (a) Schematic 166 
representation of the blood-brain barrier (BBB), composed of brain Endothelial cells (ECs) vessels 167 
overlapped by pericytes (PCs) and astrocytes (ACs) endfeet. (b, (i)) Schematic representation of 168 
proposed 3D BBB microvascular network (μVN) model that mimics the microvascular structure 169 
present in the brain environment. (b, (ii)) Confocal image of self-assembled BBB μVN model 170 
including iPSC-ECs (CD31, green), PCs (F-actin, red) and ACs (GFAP, magenta), and nuclei (DAPI, 171 
blue). (c) Microfluidic device fabrication: (c, (i)) PDMS mold with patterned channels were produced 172 
by soft lithography and bonded to a glass coverslip. The central gel region contained cells and 173 
hydrogels, side channels and reservoirs were filled with cell culture medium. (c, (ii)) A photo of the 174 
microfluidic device. (d) Timeline of the experiments. (e) Cell seeding configuration and experimental 175 
steps of vasculogenesis process of BBB μVN model including iPSC-ECs+PCs+ACs as self-176 
assembled microvascular network and 3-dimensional ECs layer covering top, bottom and side 177 
surfaces of the fluidic channel. Scale bar (b, (ii)) indicates 100 µm. 178 
  179 
Immunocytochemistry and confocal imaging 180 
The 3D BBB μVNs were cultured for 7 days followed by rinsing in PBS and fixation in 4% 181 
paraformaldehyde (PFA, Electron Microscopy Sciences) for 15 min at RT. Cell membranes were 182 
permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 5 min at RT and washed twice with PBS. 183 
Primary antibodies (1:100, volume ratio) against CD31, Glial Fibrillary Acidic Protein (GFAP), 184 
(Abcam), F-actin (Rhodamine Phalloidin, Molecular Probes), 4',6-Diamidino-2-Phenylindole (DAPI 185 
Thermo Fisher Scientific), were used to identify, respectively, iPSC-ECs, ACs, PCs, and nuclei.  186 
F-actin is strongly expressed in all cells present in our model, whereas only iPSC-ECs highly express 187 
CD31 and only astrocytes express GFAP.  We therefore used double staining of CD31/F-actin to 188 
identify iPSC-ECs and GFAP/F-actin to identify ACs, which enabled us to clearly identify the PC 189 
population as those cells that only express F-actin.  190 
To characterize the presence of TJs and ECM proteins by immunocytochemistry, primary antibodies 191 
were used against: ZO-1 (Invitrogen), occludin, claudin-5, laminin and collagen IV (Abcam). 192 
Secondary antibodies (1:200, volume ratio) were anti-rabbit or anti-mouse IgG conjugated with Alexa 193 
Fluor (488-555, or 647) (Invitrogen). Detail on primary and secondary antibodies are listed in 194 
Supplementary Table 2. Devices were incubated with primary and secondary antibodies overnight at 195 
4°C, placed on a shaker. After PBS washing, devices were imaged using a confocal laser scanning 196 
microscope (FMV-1000, Olympus, Japan) (aspect ratio 1024×1024) high resolution images at 197 
10us/pixel scan velocity. Phase contrast imaging was used for morphological observations at different 198 
culture time-points (Axiovert 200, Zeiss, Germany). Post-processing and stitching for tiled images 199 
were performed using Imaris (Bitplane, Switzerland) and Fluoview (Olympus, Japan).  Fold change 200 
average immunofluorescent (IF) intensity (relative to iPSC-ECs) was calculated by dividing total 201 
immunofluorescent intensity by cell boundary length (ZO-1, occludin, and claudin-5) or by 202 
vascularized area (laminin, collagen IV). ROIs were selected to contain only microvascular portions 203 
such that no part outside the vessels were included in the computations. 204 
 205 
Characterization of BBB microvascular parameters 206 
To characterize microvascular parameters, confocal images were analyzed using ImageJ software 207 
(http://rsbweb.nih.gov/ij/) and plugins (Trainable Weka Segmentation 3D, 3D geometrical measure). 208 
Briefly, raw images were prepared by enhancing contrast and removing noise. An automatic threshold 209 
was used to produce binarized images. From 2D projections, lateral vessel area (Alateral), and total 210 
branch length (Lbranch) were computed by ImageJ. Percentage of area coverage was calculated 211 
dividing Alateral by the entire area of the region of interest. Taking advantage of the observation that 212 
most vessels are oriented in a plane parallel to the glass substrate, lateral diameters, parallel to the 213 
glass substrates of the devices, were computed as the ratio of the projected lateral vessel area to the 214 
total branch length. Transverse diameters, perpendicular to the glass substrate, were computed using 215 
the 3D vessel volume (𝑉) and the surface area of the vessels in 3D (Asurface). Average cross-section 216 
area and circularity were computed using lateral and transverse diameters. The sequences of 217 
instructions and equations used to compute both diameters, cross-section, lateral and surface areas 218 
and circularity are shown in Supplementary methods. 219 
 220 
Microvascular network perfusion and fluorescent dextran-based permeability assay 221 
To assess permeability of the 3D BBB model, solutions containing 10 or 40 kDa FITC-dextran 222 
(Sigma-Aldrich) were introduced as fluorescent tracers, and time-sequential images to assess leakage 223 
through the microvascular barrier were captured. Briefly, after 7 days of culture, each device was 224 
moved to the confocal conditioning chamber (37°C, 5% CO2), culture medium was aspirated from 225 
all reservoirs in each side channel. Then, 5 µl of dextran solution in PBS was injected in one side, 226 
simultaneously with 5 µl of medium on the other fluidic channel to maintain equal hydrostatic 227 
pressures in the device. Confocal images were acquired every 3-5 min for 6 to 8 times to create the 228 
entire 3D stack of the gel volume with microvascular formation at each time point. ROIs were selected 229 
considering vascular networks with a clear boundary between vessel wall and gel regions. 230 
 231 
To assess perfusability, fluorescent tracers (FITC-dextran) were introduced through the 232 
microvascular networks by imposing a hydrostatic pressure drop across the gel region between two 233 
medium channels. Videos were recorded using NIS-Elements software (NIKON) on a fluorescent 234 
microscope (Nikon, TI-E ECLIPSE.) at 30 frames per second. 235 
 236 
Quantification of vessel permeability coefficient 237 
The vascular permeability is evaluated as the flux of solute across the walls of the vascular network. 238 
Using mass conservation, the quantity of FITC-dextran crossing the vascular network equals the rate 239 
at which it accumulates outside the vessels in the tissue gel region. According to a previously 240 
described method[40], vascular network permeability, Pv, was quantified by obtaining the average 241 
intensity of vessels Iv  and tissue (outside vessels) IT at two different time points t1 and t2 and using: 242 
𝑃𝑣 =
1
(𝐼𝑉
𝑡1 − 𝐼𝑇
𝑡1)
(𝐼𝑇
𝑡2 − 𝐼𝑇
𝑡1)
∆𝑡
𝑉
𝐴𝑠𝑢𝑟𝑓𝑎𝑐𝑒
 243 
 244 
Here, Δt is the time between two images, V is the tissue volume, Asurface is the surface area of all 245 
vessels in the selected ROI, computed based on the assumption that the ratio V/Asurface can be 246 
estimated as the tissue area Alateral divided by the perimeter of the vascular region Lbranch in the 247 
projected 2D images from the 3D confocal stacks. Diffusion of fluorescent dextran into the gel was 248 
minimized by introducing an iPSC-ECs monolayer in both side channels. The fluorescence intensity 249 
values, vessel surface area and tissue/gel region area were computed using ImageJ. 250 
  251 
RNA isolation and quantitative RT-PCR 252 
Total RNA was isolated from different conditions using TRIzol reagent (Life Science) for dissolving 253 
fibrin gel. Reverse transcription was performed using SuperScript VILO cDNA synthesis kit 254 
(Invitrogen). Quantitative Real-time RT-PCR (RT-PCR) using SYBR Premix Ex Taq (Takara) or 255 
Power SYBR Green PCR Master Mix, was performed with a 7900HT Fast Real-Time PCR System 256 
(Applied Biosystems). mRNA of endothelial cell adhesion molecule (PECAM-1) also known CD31, 257 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Ribosomal Protein S18 (RPS18) were 258 
used as housekeeping genes, set to 100% as the internal standard. RT-PCR experiments were repeated 259 
at least 3 times for cDNA prepared from 6 devices. Primer sequences (Integrated DNA technology) 260 
are listed in supplementary Table 1. RT-PCR was performed in a scaled up version a of the device 261 
(Supplementary Fig. 1b) in order to collect higher amount of total RNA. 262 
 263 
Statistical analysis 264 
All data are plotted as mean ± SD. One-way ANOVA with pairwise comparisons by the Tukey post 265 
hoc test was used to determine whether three or more data-sets were statistically significant. Statistical 266 
tests were performed using JMP pro (SAS Institutes, Inc.). At least four devices (≥2 regions per 267 
device) for each condition within 3 independent experiments were used for the imaging and data 268 
analysis. **** denotes p < 0.0001, *** denotes p < 0.001, ** denotes p < 0.01, * denotes p < 0.05. 269 
Non-paired student’s t-test was used for significance testing between two conditions. 270 
  271 
Results 272 
 273 
Optimization of self-assembled microvasculature 274 
Three models were established, as described in Methods, with progressively greater complexity: (i) 275 
iPSC-ECs (Fig. 2a,b (i)), (ii) iPSC-ECs + PCs (Fig. 2a,b (ii)), and (iii) iPSC-ECs + PCs + ACs (Fig. 276 
2a,b (iii), Supplementary Figs. 4a-c). In each case, the iPSC-ECs elongated and intracellular 277 
intussusception and vacuoles appeared after 1 day followed by the formation of lumen structures after 278 
2-3 days (Supplementary Figs. 2a and 3a,b). Further development of the μVNs resulted in a highly 279 
interconnected microvasculature by day 7 of the culture (Fig. 2b).  280 
 281 
With iPSC-ECs alone (Fig. 2a,b (i)),  vascular networks formed in 4-5 days (Supplementary Fig. 2a), 282 
however, the vessels fused, forming large, elliptical cross-section lumens, many of which contacted 283 
the bottom coverslip (Fig. 3a) and gradually degraded and regressed after 7 days (Supplementary Fig. 284 
5a). In contrast, co-culture of iPSC-ECs with PCs formed smaller and more highly branched vessels 285 
(Figs. 2a,b (ii), 3b). No significant difference could be observed when iPSC-ECs were cultured alone 286 
or with PC conditioned medium (Supplementary Fig. 5b), suggesting that contact with PCs effectively 287 
facilitated endothelial organization, by stabilizing a mature vasculature with a morphology more 288 
similar to that found in vivo.  289 
 290 
The addition of ACs further assisted in the development of a complex inter-connected and branched 291 
architecture found in native vasculatures (Fig. 2a,b (iii), Supplementary Fig. 3a,b).  In tri-culture with 292 
ACs, the μVNs exhibited distinctive behavior during formation, with increased tortuosity and vessels 293 
extending higher up in the 3D gel (Fig. 3c). A fundamental characteristic of the BBB is the stratified 294 
organization of cells around the vessels and their direct contact interactions. In 4 replicates with 10-295 
12 high resolution confocal images, we observed a spontaneous self-organization into multicellular 296 
BBB structures. Indeed, PCs (F-actin, red, Fig. 2c) adhered to both sides of the endothelial cell 297 
Commentato [CM1]: If reviewer would like to specify 
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surface, surrounding the vessel (CD31, green, Fig. 2c,e, Supplementary Fig. 6a, Supplementary video 298 
1). For example, tracing the intensity profiles of EC and PC fluorescence (Fig. 2d), F-actin expression 299 
was observed outside the vessel, clearly delineating the presence of PCs. These results showed that 300 
pericytes partially overlapped the outer surface of the EC layer exhibiting a BBB-like organization. 301 
In addition, 3D rendering of vessel bifurcations showed PCs in contact with the endothelium at 302 
multiple locations (Fig. 2e). Moreover, direct physical contacts were observed between AC endfeet 303 
(Glial Fibrillary Acidic Protein, (GFAP), violet) and the abluminal surface of the brain vessels (CD31, 304 
green, Fig. 2f; Supplementary Figs. 6b,c).  305 
 306 
Characterization of microvascular parameters  307 
To determine the geometrical changes in the μVNs (Fig. 3a-c, Supplementary Fig.4a-c), lateral and 308 
transverse vessel diameter distributions, percentage of image area containing vascular networks, and 309 
total branch length were each quantified (Fig. 3d-i). As expected, in the iPSC-ECs+PCs co-culture, 310 
the lateral vessel diameters (30 to 100 µm, Fig. 3e (i)) were significantly lower than in mono-culture 311 
conditions (50 to 150 µm with a few outliers to 200 µm, Fig. 3d (i)). Lateral diameters were further 312 
reduced by adding ACs (most values between 25 and 50 μm (Fig. 3f (i))). The overall transverse 313 
diameter distributions were similar for all three conditions, ranging between 10 and 40 μm, and 314 
centered around 30 μm (Fig. 3d-f (ii)).  315 
 316 
Figure 2: Microvascular network conditions iPSC-ECs - PCs/ACs contact interactions. (a) 317 
Schematic representation and (b) confocal images of (a, b, (i)) iPSC-ECs mono-culture (CD31, 318 
green), (a, b, (ii)) co-culture with PCs (F-actin, red), and (a, b, (iii)) tri-culture with PCs and ACs 319 
(GFAP, magenta), after 7 days of culture in the microfluidic device. (c) Cross-sectional images of 320 
blood microvessels showing hollow lumens. (c, (i)) PCs adhered to and partially enveloped brain 321 
microvessel. (c, (ii)) Cross-sectional images of blood microvessels showing a lumen enclosed by 322 
iPSC-ECs and PCs. PCs surround the blood vessel. Image shows how section was sampled using a 323 
line scan measurement (yellow line) and generation of intensity profile histogram. (d) Intensity 324 
profile analysis of CD31/F-actin in iPSC-ECs -PCs interaction corresponding to the yellow line scan. 325 
Intensity profile shows distinct peaks (yellow arrow) at the position of contact interaction/overlapping 326 
between ECs and PCs. CD31 expression (green) was low when F-actin expression (red) was high, 327 
further indicating that F-actin expression belonged only to brain PCs outside the vessels. Region of 328 
low green intensity corresponds to the vascular bed of the vessel. (e) Contact interactions of PCs 329 
enveloping blood microvessel. PCs adhered to and partially enveloped brain microvessel. (f) 330 
Confocal image of iPSC-ECs, PCs and ACs in the tri-culture condition. Images were analyzed using 331 
Imaris 8.3. Scale bars indicate 100 µm (b) and 20 µm (c, e, f). 332 
333 
 334 
Figure 3: 3D BBB microvascular network parameter quantification. Confocal images of laminin 335 
expression (red) and nuclei (DAPI, blue) of 3D BBB μVN maturation from (a) mono-culture of iPSC-336 
ECs, (b) co-culture of iPSC-ECs+PCs and (c) tri-culture of iPSC-ECs+PCs+ACs (scale bar: 100 µm). 337 
Distribution of lateral and transverse vessel diameter measurements of 3D BBB μVNs formed by 338 
vasculogenesis, for (d) mono-culture of iPSC-ECs, (e) co-culture with brain PCs, (f) tri-culture with 339 
brain PCs and ACs. Additional image in supplementary Fig. 4. (g, h, i) Quantification of 340 
microvascular network parameters: (g) average lateral and transverse vessel diameters in each 341 
condition, (h) microvascular branches average length and (i) percentage ratio of microvascular 342 
network area coverage to the total area. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. Error bars 343 
± SD, n=30. 344 
Hence, lumens with nearly circular cross-section and consequently smaller cross-section area and 345 
higher circularity (Supplementary Fig. 6d-f) formed in the tri-culture condition (average lateral 346 
diameter: 42 ± 13 μm, average transverse diameter: 25 ± 6 μm, Fig. 3g), while lumens were flattened 347 
and had elliptical cross-section in mono-cultures (average lateral diameter: 108 ± 14 μm, average 348 
transverse diameter: 29 ± 10 μm, Fig. 3g), and in co-cultures (average lateral diameter: 64 ± 13 μm, 349 
average transverse diameter: 27 ± 7 μm, Fig. 3g).  350 
 351 
Moreover, the cumulative average μVN branch length decreased from mono-culture (226 ± 40 µm), 352 
to co-culture (179 ± 31 µm), and tri-culture (136 ± 24 µm) conditions, respectively (Fig. 3h), 353 
demonstrating a highly complex and intertwined vascular network. Accordingly, the networks with 354 
iPSC-ECs, iPSC-ECs+PCs, and iPSC-ECs+PCs+ACs conditions covered progressively less area in 355 
the projected image (62%, 42%, and 28%, respectively (Fig. 3i). Indeed, in tri-culture conditions, the 356 
μVNs showed improved morphology provided by the co-culture with ACs and PCs, with reduced 357 
vessel diameters and average branch length. These results mirror similar observations that have been 358 
attributed to the secretion of angiogenic growth factors by PCs and ACs [19][20].  359 
 360 
In summary, these results indicate that the networks formed with all three cell types --iPSC-361 
ECs+PCs+ACs -- contained more stable and shorter vessel branches, with more circular cross-362 
sections and smaller vessel diameters compared to the other conditions. These networks also 363 
exhibited more random interconnections and improved 3D structural orientation into the gel region: 364 
such structure is more similar to in vivo vessel morphology [30]. 365 
 366 
Protein synthesis and gene expression related to blood-brain barrier (BBB) 367 
To analyze whether the engineered 3D brain microvascular model constitutes a functional barrier and 368 
exhibits physiological characteristics typical of the BBB present in vivo, we validated and compared 369 
protein expression measured by immunocytochemistry assays and quantitative real-time RT-PCR, 370 
performed after 7 days. Firstly, immunocytochemistry images of vascular networks obtained under 371 
different culture conditions were compared from multiple regions of interest (ROIs) within the 372 
vessels. The expression of endothelial-specific junction proteins ZO-1, occludin, and claudin-5 (Fig. 373 
4a-c), and ECM constituents such as laminin (Fig. 4d) and collagen IV (Fig. 4e) was analyzed by 374 
confocal microscopy (See also Supplementary fig. 7b-f). Interestingly, the increase of TJ protein 375 
expression in μVNs was observed by introducing PCs and ACs (Fig. 4a-c). Therefore, the BBB μVNs 376 
obtained by iPSC-ECs+PCs+ACs tri-culture (Fig. 4a (iii)) relatively expressed much higher level of 377 
ZO-1, occludin and claudin-5 compared to mono-culture of iPSC-ECs and iPSC-ECs+PCs (Fig. 4a-378 
c). Quantitative analysis of fold change average immunofluorescent (IF) intensity (relative to iPSC-379 
ECs) confirmed qualitative observations (Fig. 4f). Average immunofluorescent (IF) intensity was 380 
calculated by dividing the total immunofluorescent intensity by the cell boundary length in each ROI 381 
in the case of tight-junction proteins (ZO-1, occludin, and claudin-5). In the case of basement 382 
membrane protein deposition (laminin, collagen IV), average IF intensity was calculated by dividing 383 
the total IF intensity by the vascularized area in each ROI. ROIs were selected to contain only 384 
microvascular portions (Fig. 4f). Continuous cell-cell junctions lining the rhomboidal boundaries of 385 
endothelial cells along lumens were observed in co-culture and tri-culture conditions, as demonstrated 386 
by the clear delineation of ZO-1 along the cell-cell border (Supplementary Fig. 7a). 387 
 388 
Another sign of vessel maturation was the deposition of basement membrane proteins, exhibiting a 389 
similar trend to TJ expression. Laminin and collagen IV immunofluorescence intensity (Fig. 4d-f) 390 
approximately doubled in the case of the microvascular networks obtained by iPSC-ECs+PCs+ACs 391 
tri-culture (Fig. 4d,e (iii)) compared to iPSC-ECs mono-culture (Fig. 4d,e (i)) and was significantly 392 
higher than for iPSC-ECs+PCs co-culture (Fig. 4d,e (ii)).   393 
Figure 4: Immunocytochemistry 394 
analysis of tight junctions and 395 
ECM deposition. Self-assembled 396 
microvascular networks formed 397 
after 7 days in microfluidic device 398 
culture for: (i) mono-culture of 399 
iPSC-ECs, (ii) co-culture with PCs 400 
and (iii) tri-culture with PCs and 401 
ACs (BBB microvascular network 402 
model). (a-e) Microvascular 403 
networks were immunostained for 404 
tight junctions (ZO-1, occludin 405 
(OCCL) and claudin-5 (CLDN 5)), 406 
and ECM production (laminin 407 
(LAM) and collagen IV (COLL 408 
IV)), and nuclei (DAPI) inside 409 
microfluidic devices and imaged by 410 
confocal microscopy. (a) 411 
Immunofluorescent (IF) intensities 412 
of ZO-1 were well-defined in co-413 
culture and tri-culture conditions. 414 
ZO-1 expression was clearly 415 
localized at the intersection between 416 
cells forming a rhomboidal grid, 417 
characteristic of mature and well-418 
organized microvasculature. 419 
Instead, monoculture exhibited low 420 
expression of TJ proteins with no 421 
visible and defined accumulation at 422 
cell boundaries. Similar behavior 423 
was exhibited by (b) occludin and 424 
(c) claudin-5. (d) Confocal images 425 
of deposition of laminin and (e) 426 
collagen IV showed production and 427 
remodelling of a distinct ECM by 428 
the different microvascular 429 
networks. BBB microvascular 430 
model with PCs and ACs expressed 431 
higher intensities of laminin and 432 
collagen IV compared to 433 
monoculture and co-culture, 434 
providing evidence that PCs and 435 
ACs improved vascular function. 436 
Qualitative image tests were 437 
realized by ROI intensity analysis. (f) Fold change average IF intensity (relative to iPSC-ECs) 438 
quantify the protein expression according to the IF images. Computed image intensities were 439 
normalized by the selected area. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. Error bars ± SD, 440 
n=8. Confocal image scale bar: 50 µm.  441 
To confirm immunocytochemistry results, total RNA was extracted from the total cell population in 442 
the microfluidic device (Fig. 5a) and purified from different conditions at several time points (day 0, 443 
4, and 7). RT-PCR analysis was conducted considering gene markers of TJ proteins, ECM production 444 
and several endothelial membrane transporters such as efflux-pumps, passive transports, solute 445 
carriers, and receptor-mediated mechanisms. Vessel maturation was investigated in terms of the 446 
expression of several markers and proteins, in the case of co-culture and tri-culture conditions, and 447 
was compared to the control condition (iPSC-ECs). The mRNA expression of each gene was 448 
measured relative to the expression of CD31 and GAPDH (fold change). TJ proteins such as ZO-1, 449 
occludin, and claudin-5 were highly up-regulated in the tri-culture condition at day 7 compared to 450 
mono-culture and co-culture conditions. Interestingly, the expression of TJ markers in the tri-culture 451 
case increased as a function of culture time (Fig. 5b, Supplementary Fig. 10a-e). As expected, GFAP 452 
was regulated exclusively in the presence of ACs. PDGFR gene expression was slightly higher in the 453 
tri-culture condition while alpha-smooth muscle actin (αSMA) expression was reduced, possibly due 454 
to the increased proliferation of iPSC-ECs and PCs stimulated by ACs. Furthermore, basement 455 
membrane proteins (collagen IV, laminin) were highly expressed over time in the tri-culture condition 456 
compared to the mono- and co-culture cases. In addition, gene expression of several BBB-specific 457 
membrane transporters and receptors which exploit several transport mechanisms (passive diffusion, 458 
ATP-binding efflux transporter, solute carriers and receptor-mediated transcytosis), such as P-GP, 459 
MRP1, MRP4, TF-R, LRP1, LAT-1, GLUT-1, CAT1, MCT1, ABCA1, and BCRP widely increased 460 
over time in the tri-culture BBB model (iPSC-ECs+PCs+ACs), compared to iPSC-ECs+PCs and 461 
iPSC-ECs microvascular network conditions. Overall after 7 days, the tri-culture condition displayed 462 
a constantly increased maturation and upregulation of all examined genes (Fig. 5b, Supplementary 463 
Fig. 10a-e, Primer sequences in Supplementary Table 1). 464 
  465 
Figure 5: Quantitative relative RT-PCR of 3D BBB μVNs in microfluidic device. (a) Schematic 466 
representation of vascular network and gel extraction from a microfluidic device, purification of total 467 
RNA and conduct of RT-PCR experiments. (b) Heatmap of RT-PCR results of mono-culture of iPSC-468 
ECs, co-culture with PCs, and tri-culture with PCs and ACs at 0, 4 and 7 days. Relative comparison 469 
of mRNA expression of factors relating to microvascular maturation and other typical BBB features.  470 
Gene analysis considered markers 1) expressed in ECs, 2) expressed in PCs, 3) expressed in ACs, 4) 471 
ECM protein RNA, and 5) genes expressed predominantly by ECs, but also in smaller amounts by 472 
the other two cell types. Fold change was relative to control (mono-culture of iPSC-ECs, day 0). The 473 
internal standard housekeeping gene was CD31. 0.01< p <0.05, n = 3.  474 
Distinct cell contributions to BBB permeability  475 
The permeability of the microvessels in our BBB μVN models was computed to assess the practical 476 
potential to use our system to mimic solute transport in vivo. In all culture conditions, vessels 477 
comprising the entire vascular network were well formed and completely perfusable at day 7 478 
(Supplementary Fig. 8d, Supplementary video 2, 3). Permeability coefficients were measured by 479 
introducing solutions containing FITC-dextran tracers in the vasculature (10 & 40 kDa), and 480 
capturing confocal images at 5 min intervals and computing themed as explained in Methods (Fig. 481 
6a-d, Supplementary Fig. a-c). With side-channels seeded with iPSC-ECs, permeability to 40 kDa 482 
FITC-dextran of the μVN obtained under mono-, co-, and tri-culture conditions progressively 483 
decreased: 6.6, 2.5, and 0.89 ×10-7 cm/s, respectively. A similar trend was observed for the 10 kDa 484 
FITC-dextran: 12, 4.8 and 2.2 ×10-7 cm/s, respectively (Fig. 6e, f). When iPSC-ECs were not added 485 
to the side channels, leakage of tracer across the side-walls of the gel region gave rise to higher 486 
permeability values, roughly a two-fold increase, due to the artifact associated with the additional 487 
source of tracer influx. Side channel seeding helped in several ways. It improved coverage of the 488 
exposed side gel surface with an endothelial monolayer, filled gaps that sometimes formed at the gel-489 
post borders, and increased the number and patency of connections between the networks and the 490 
main channel (Fig. 7a and Supplementary Fig. 9a-e). 491 
  492 
 493 
Figure 6: Permeability assay in BBB model. (a) Timeline of permeability experiments and 494 
computational analysis. After cell culture medium was removed, dextran solution was injected and 495 
image stacks were captured every 3-5 mins for 30 mins. Workflow of image analysis by ImageJ and 496 
permeability coefficient calculation. (b) Confocal and bright field images at time 0. (c) Image 497 
binarization after thresholding to identify vessel borders. (d, (i-iv)) Maximum image projections and 498 
cross-sections including xy, xz and yz planes at 4 time-points. The graphs show permeability 499 
coefficients for 3 different conditions (with and without ECs seeding in side channels) using (e) 40 500 
kDa and (f) 10 kDa FTIC-dextrans in mono-culture of iPSC-ECs, co-culture of iPSC-ECs+PCs, and 501 
tri-culture of iPSC-ECs+PCs+ACs. The data show mean value, error bars ± SD, n=10, * p<0.05, ** 502 
p<0.01, *** p<0.001, **** p<0.0001, scale bars 50 µm.  503 
 504 
Figure 7: BBB microvascular network model. (a) Confocal images of xy and xz (cross-section) 505 
planes of the 3D BBB microvascular in vitro model with iPSC-ECs+PCs+ACs, including EC layers 506 
in the side channel. Scale bars 200 µm.   507 
Discussion 508 
 509 
In this work, we developed a new in vitro human BBB microvascular model consisting of a self-510 
assembled μVN of iPSC-ECs co-cultured with brain PCs and ACs. Novelty of our microfluidic 511 
platform arises from simultaneous seeding of three human cell types into a single gel region, 512 
producing a perfusable vascular network, with permeabilities lower than those of other published 513 
microfluidic models [23][24][27][32][34]. 514 
 515 
iPSC-ECs were selected as they are immature endothelial cells, capable of organizing into a complex 516 
and perfusable vascular network [41], with lower permeability values compared to other non-brain 517 
EC models [42][43][44]. The potential features of iPSC-ECs may contribute to a coherent and 518 
relevant replacement of “brain” endothelial cells to establish a 3D BBB microvascular model. 519 
Moreover, iPS cells may be potentially derived from patients who suffer from specific 520 
neurodegenerative diseases [45], thereby producing a pathological model to study disease progression, 521 
to screen for drugs appropriate for patients’ sub-groups, or even for precision medicine applications 522 
to select optimal, personalized therapies.  523 
 524 
Our 3D BBB μVN model incorporating three cell-types (Fig. 1b and Fig. 7a) expressed both 525 
functional and morphological characteristics present in the human BBB, with stable and perfusable 526 
μVNs, comprising small lumens with circular cross-section comparable with in vivo human 527 
microcirculation (arterioles and venules <100 µm; capillaries <10 µm) [28][29]. It also defined 528 
microvascular branch length similar to segments in close proximity to the third ventricle (caudate, 529 
putamen, and thalamus with an average of 70 µm) [46] and characterized by low permeability and 530 
transport selectivity (Fig. 6e,f and Supplementary movie 2, 3). It draws upon the intrinsic nature of 531 
ECs interacting with other neural cell types to recapitulate brain vascular morphogenesis during 532 
developmental process via vasculogenesis [47][48], in which immature ECs recruit PCs and ACs to 533 
form new vessels through PDGFR and Sonic hedgehog (SHH) signaling pathways [47][49]. In 534 
particular, PCs played an important role to create a robust and stable vessel network with significant 535 
lateral diameter reduction (Fig. 3d,g). It has been previously demonstrated that ECs need a 536 
combination of juxtacrine and paracrine signaling to create a stable and physiologically-relevant 537 
microvasculature on a chip [38][39]. Hence, the resulting formation of a physiologically-relevant 538 
microvasculature, was facilitated by juxtacrine interactions and paracrine signaling between iPSC-539 
ECs and PCs (enveloping the endothelium) (Fig. 2c-e), along with the increase of TJ expression and 540 
appropriate concentration of growth factors (Fig. 4a-c, Supplementary Figs. 7a-d, 10a-d). Indeed, 541 
improvements were associated with the presence and secretion of vascular endothelial growth factor 542 
VEGF (50 ng/ml in the supplemented medium), angiopoietin-1 (ANG-1) and fibroblast growth factor 543 
(FGF) by stromal cells, especially PCs [50]. However,  as VEGF could modulate vascular 544 
permeability through the disruption of tight junctions and consequent break down  of the BBB [51], 545 
cell culture medium was supplemented with VEGF up to day 4. 546 
 547 
We hypothesize that this morphological change in the final structure of the BBB μVNs was induced 548 
by not only the presence and cell-secretion of pro-angiogenic and vasculogenic growth factors and 549 
ECM proteins, but also by juxtacrine signaling, consistent with previous findings [35][52][53]. Our 550 
results also suggest that PCs not only influence the creation of vascular networks but also induce the 551 
differentiation of iPSC-ECs into brain-specific endothelial cells, as determined by the RT-PCR results 552 
(Fig. 5b, Supplementary Fig. 10a-d). Indeed, it has already been shown that co-culture of ECs with 553 
PCs is required for BBB formation and the maintenance of homeostasis by contact and paracrine 554 
interactions [54].  555 
 556 
In addition to the contribution of PCs, ACs also improved BBB formation and integrity. iPSC-ECs 557 
self-assembled into mature vascular networks forming complex structures when interacting with both 558 
cell types. The role of ACs was evidenced by an increase in the expression of BBB transporters and 559 
TJ proteins, such as ZO-1, occludin, claudin-5, ECM deposition (Figs. 4a-e, 5b, Supplementary Fig. 560 
7a-c), and the corresponding decrease in permeability, (Fig. 6e-f) similar to previous transwell and 561 
microfluidic-based models incorporating ACs [55]. In particular, the upregulation of typical BBB 562 
transporters such GLUT-1, LAT-1, PG-P, TF-R, LRP1 and MRPs is fundamental to obtain an in vitro 563 
BBB model for drug design and testing. Indeed, these specific transporters were highlighted as 564 
potential targets to enhance the penetration of drugs into the brain [56] (Supplementary Fig. 10d).  565 
 566 
In our model, AC endfeet were directly attached to the surface of vascular networks in the 3D matrix 567 
(Fig. 2f, Supplementary Fig. 6b,c). This morphological feature of ACs recapitulates their 568 
physiological arrangement in the brain and provides mutual biochemical support for those cells, 569 
helping to maintain the integrity of the neurovascular networks [57]. Our findings suggest that the 570 
addition of ACs is in part responsible for the improved morphology of BBB anatomical structure. 571 
They might also contribute through paracrine signals to the development of a BBB-like endothelial 572 
phenotype since ACs are known to regulate influx/efflux, vasodilatation/vasoconstriction by inducing 573 
tightening of the endothelium [19], as well as cytokine and growth factor secretion such as basic FGF, 574 
glial-derived neurotrophic factor (GDNF), and ANG-1 [58]. Further investigation is needed to 575 
ascertain the relative importance of different biological pathways and factors improving BBB 576 
integrity, however, direct adhesion of ECs, PCs and ACs might facilitate N-cadherin cell-cell 577 
interactions [47].  578 
 579 
As key features in assessing the value of BBB microvascular models for drug transport studies, 580 
vascular perfusability and permeability were measured using fluorescent probes. The vessel networks 581 
in our tri-culture BBB model attained permeability values of 8.9×10-8 cm/s and 2.2×10-7 cm/s for 40 582 
kDa and 10 kDa FTIC-dextran, respectively (Fig. 6e,f), confirming barrier selectivity depending on 583 
their molecular weight [59].  584 
Importantly, these values are comparable to those measured in vivo in rat cerebral microcirculation 585 
(3.1 ± 1.3×10-7 cm/s for a 10 kDa FITC-dextran) [60], (1.37± 0.26×10-7 cm/s for a 40 kDa FITC-586 
dextran) [61], and similar to specific models that employ brain ECs derived from iPSCs (IMR90-4) 587 
by co-culturing with astrocytes and/or neurons [62][63], and lower than previously reported 3D 588 
[23][27][32][34], or 2D BBB models [24][64]. 589 
 590 
As a side note, inclusion of an iPSC-EC monolayer in the adjacent fluidic channels improved vascular 591 
perfusability and also reduced the artifacts associated with tracer leakage across the sidewalls of the 592 
gel region (Fig. 7, Supplementary Fig. 9a-e). Consistent with the progressive reduction in 593 
permeability with increasing model complexity, we observed a corresponding increase in the tightness 594 
of junctional proteins and their regulation [53][65], evaluated by immunostaining and RT-PCR 595 
analysis. This contrasts with a previous study that reported an increase in permeability coefficient 596 
when human brain endothelial cells (hCMEC/d3) were co-cultured with ACs isolated from rats [32], 597 
possibly due to cross-species effects, as suggested by the authors of [29].  598 
 599 
It is important to note that our model lacked neurons and microglia, and these might have further 600 
effects on barrier functionality. Recent literature has shown that the upregulation of BBB-specific 601 
transporters and the differentiation of brain-specific ECs are induced by the co-culture of iPSC-ECs 602 
with iPS derived neurons [66]. In the same model authors demonstrated the possibility of drug 603 
screening using iPSC-ECs in combination with all human iPS derived cells using transwell methods. 604 
Also, co-culture with neural iPSCs has been found to improve EC barrier integrity and decrease 605 
vascular permeability [66]. Therefore, there appear to be additional advantages gained by an even 606 
more comprehensive human patient-derived in vitro model [66], combining iPSCs and/or neural stem 607 
cells with the vascular networks, PCs, and ACs described here. Moreover, using iPS cells derived 608 
from patients affected by neurological disorders [45], such as Alzheimer’s disease, a BBB 609 
pathological model could be obtained. 610 
 611 
Our 3D self-organized system has several advantages compared to the in vitro 2D membrane-based 612 
monolayer, including its more physiologically-relevant morphology. Permeability measurements, 613 
however, at this point are limited to quantifying concentrations of a fluorescent tracer.  Similar 614 
measurements could be made by tagging the molecule of interest with a fluorescent marker using this 615 
same experimental protocol.  Alternatively, samples of interstitial fluid could be directly collected 616 
from the gel filling ports in the device, and used to quantify transport into the matrix, but this could 617 
be problematic due to the low drug concentrations in the gel region. 618 
Although PDMS is widely used for microfluidic applications, one of its disadvantages is non-specific 619 
adsorption of proteins and small hydrophobic molecules during long-term interaction [67]. Even 620 
though this would not have affected our current permeability study, in perspective of drug testing, 621 
several treatments exist to prevent fouling of the PDMS surface. Accordingly, distinct surface 622 
modifications that could reduce non-specific absorption include coating the PDMS surface with 623 
bovine serum albumin (BSA) [68],  grafting with anti-fouling molecules [69], or silanization [70]. 624 
 625 
Other possible improvements to the current model are the introduction of continuous perfusion to 626 
improve microvascular formation and reduce vascular permeability in the perspective of a long-term 627 
culture system. Indeed, flow perfusion culture could advance the model in two important aspects. 628 
Firstly, oxygen and glucose transport into the vessels will tend to modulate glycolytic metabolism in 629 
favor of the more efficient aerobic respiration useful for maintaining a long-term culture. Secondly, 630 
flow-mediated shear stress is known to promote the differentiation of vascular endothelial cells into 631 
a more BBB-like phenotype with the highest expression of TJ proteins and membrane transporters, 632 
producing further reductions in permeability [71]. Finally, it would be beneficial to assess the trans-633 
endothelial electrical resistance (TEER) measurement as another metric of BBB function [24]. 634 
  635 
Conclusion 636 
 637 
Here we present the first highly functional 3D BBB in vitro model produced by vasculogenesis that 638 
incorporate human iPSC-ECs microvascular network in contact interaction with human brain PCs 639 
and ACs within a single 3D ECM/fibrin gel region. Our 3D BBB microvascular model exhibits 640 
physiologically relevant structures and provides an effective and reproducible platform compared to 641 
static models [16][17], useful in the study of dynamic transport of small and large molecules across 642 
the BBB in a complex microenvironment [72]. We believe this is a reliable and valuable next-643 
generation system that furthers the understanding of neurovascular function, enables the preclinical 644 
development of effective CNS therapeutics [16], can be applied to probe metastatic cancer 645 
extravasation [26][73] and evaluate reciprocal brain-systemic circulation interactions that occur in 646 
inflammatory and neurodegenerative diseases [4-9]. This translational model could be adapted for the 647 
high-throughput pre-clinical screening of innovative therapies targeting specific BBB transporters, to 648 
perform drug delivery studies and to investigate the transport of microengineered nanocarriers able 649 
to cross the BBB.   650 
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